Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-02022024-251750
EXTRAORDINARY
PART II—Section 3—Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 399]
NEW DELHI, FRIDAY, FEBRUARY 2, 2024/MAGHA 13, 1945
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 2nd February, 2024
S.O. 423(E). In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below
as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the
corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing
company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| Sl. | Name of the | Strength | Unit | Manufacturer & | Retail |
| No. | Formulation / | | | Marketing Company | Price |
| | Brand Name | | | | (Rs.) |
+=====+==================================+=============================================================+===========+==============================================+==============+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 1 | Paracetamol and | Each uncoated tablet contains: | 1 Tablet | M/s Prosperity Drugs | 2.12 |
| | Dicyclomine | Paracetamol IP 325mg | | Pvt. Ltd./M/s Torrent | |
| | Hydrochloride | Dicyclomine Hydrochloride IP | | Pharmaceuticals | |
| | Tablets | 20mg | | Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 2 | Albendazole & | Each 5ml contains: | 1 ml | M/s. Prochem | 1.36 |
| | Ivermectin | Albendazole IP 200mg | | Pharmaceuticals Pvt. | |
| | Suspension | Ivermectin IP 3mg | | Ltd. / M/s Indoco | |
| | | | | Remedies Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 3 | Amoxycillin and | Each 5ml of reconstituted | 1 ml | M/s Alps | 3.17 |
| | Potassium | suspension contains: | | Communication Pvt. | |
| | Clavulanate Oral | Amoxycillin Trihydrate IP eq. to | | Ltd. / M/s Aristo | |
| | Suspension | Amoxycillin 600mg | | Pharmaceuticals Pvt. | |
| | | Potassium Clavulanate Diluted IP | | Ltd. | |
| | | eq. to Clavulanic Acid 42.9mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 4 | Cefuroxime Axetil | Each film coated tablet contains: | 1 Tablet | M/s Theon | 56.98 |
| | & Potassium | Cefuroxime Axetil IP eq. to | | Pharmaceuticals Ltd. / | |
| | Clavulanate IP | Anhydrous Cefuroxime 500mg | | M/s Torrent | |
| | Tablets | Potassium Clavulanate Diluted IP | | Pharmaceuticals Ltd. | |
| | | Eq. to Clavulanic Acid 125mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 5 | Amoxycillin and | Each film coated tablet contains: | 1 Tablet | M/s Brooks | 40.03 |
| | Potassium | Amoxycillin Trihydrate IP eq. to | | Laboratories Ltd. / M/s | |
| | Clavulanate Tablets | Amoxycillin 875mg | | German Remedies | |
| | IP | Potassium Clavulanate Diluted IP | | Pharmaceuticals | |
| | | eq. to Clavulanic Acid 125mg | | Private Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 6 | Zolpidem Tartrate | Each film coated bilayered | 1 Tablet | M/s Abbott India | 14.12 |
| | Prolonged release | Prolonged release tablets | | Limited | |
| | tablets | contains: | | | |
| | | Zolpidem Tartrate IP 12.50mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 7 | Zolpidem Tartrate | Each film coated bilayered | 1 Tablet | M/s Abbott India | 11.41 |
| | Prolonged release | Prolonged release tablets | | Limited | |
| | tablets | contains: | | | |
| | | Zolpidem Tartrate IP 6.25mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 8 | Meropenem and | Each vial contains: | 1 vial | M/s Aqua Vitoe | 1584.24 |
| | Sulbactum for | Meropenem IP (Sterile) eq. to | | Laboratories / M/s | |
| | Injection | Anhydrous Meropenem 1000mg | | FDC Limited | |
| | | Sodium Carbonate IP (As buffer) | | | |
| | | eq. to Sodium 90.2mg | | | |
| | | Sulbactam Sodium IP (Sterile) eq. | | | |
| | | to Sulbactum 500mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 9 | Rosuvastatin + | Each Hard gelatin capsule | 1 Capsule | M/s Pure and cure | 19.21 |
| | Clopidogrel | contains: | | Healthcare Pvt. Ltd. / | |
| | Capsules | Rosuvastatin Calcium IP Eq. to | | Dr. Reddy's | |
| | | Rosuvastatin 20mg (As film coated | | Laboratories Limited | |
| | | Tablet form)Clopidogrel Bisulphate | | | |
| | | IP Eq. to Clopidogrel 75mg (As | | | |
| | | Film coated Tablet form) | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 10 | Diclofenac | Contains: | 1 gram | M/s Curetech Skincare | 3.41 |
| | Diethylamine, | Diclofenac Diethylamine IP 1.16% | | / M/s J.B. Chemicals & | |
| | Virgin Linseed Oil, | w/w, | | Pharmaceuticals Ltd. | |
| | Methyl Salicylate, | Virgin Linseed Oil BP 3% w/w, | | | |
| | Menthol & Capsacin | Methyl Salicylate 10% w/w, | | | |
| | Gel | Menthol IP 5% w/w | | | |
| | | Capsacin USP 0.025% w/w | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 11 | Omeprazole & | Each hard gelatin capsule | 1 Capsule | M/s Innova Captab | 6.18 |
| | Domperidone | contains: | | Limited / M/s Eris | |
| | Capsules IP | Omeprazole IP 20mg (as enteric | | Healthcare Pvt. Ltd. | |
| | | coated pallets) | | | |
| | | Domperidone IP 10mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 12 | Linagliptin, | Each film coated bilayered tablet | 1 Tablet | M/s Synokem | 9.18 |
| | Metformin | contains: | | Pharmaceuticals | |
| | Hydrochloride | Linagliptin 2.5mg | | Limited / M/s Mankind | |
| | (Extended Release) | Metformin Hydrochloride IP | | Pharma Limited | |
| | Tablets | 1000mg (As Extended Release) | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 13 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 11.61 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Micro Labs Limited | |
| | Hydrochloride and | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 14 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Mascot Health | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Series Pvt. Ltd. / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Lupin Limited | |
| | Hydrochloride and | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 15 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Abbott Healthcare Pvt. | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Ltd. | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 16 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Synokem | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals Ltd. / | |
| | Metformin | IP eq. to Sitagliptin 50mg | | M/s Mankind Pharma | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 17 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Glenmark | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 18 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Emcure | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg Glimepiride IP 1 mg | | Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 19 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Torrent | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 20 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Eris Lifesciences | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 21 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Synokem | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals Ltd. / | |
| | Metformin | IP eq. to Sitagliptin 50mg | | M/s Torrent | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 22 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.35 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Dr. Reddy's | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Laboratories Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 23 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 13.39 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Micro Labs Limited | |
| | Hydrochloride and | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 24 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Abbott Healthcare Pvt. | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Ltd. | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 25 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Glenmark | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 26 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Synokem | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals Ltd. / | |
| | Metformin | IP eq. to Sitagliptin 50mg | | M/s Mankind Pharma | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 27 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Mascot Health | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Series Pvt. Ltd. / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Lupin Limited | |
| | Hydrochloride and | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 28 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Emcure | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg Glimepiride IP 2 mg | | Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 29 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 14.30 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Torrent | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 30 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Synokem | 14.30 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals Ltd. / | |
| | Metformin | IP eq. to Sitagliptin 50mg | | M/s Torrent | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Pharmaceuticals | |
| | Glimepiride Tablets | 1000mg | | Limited | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 31 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Dr. Reddy's | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Laboratories Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 32 | Sitagliptin | Each film coated tablet contains: | 1 Tablet | M/s Exemed | 15.03 |
| | Phosphate, | Sitagliptin Phosphate Monohydrate | | Pharmaceuticals / M/s | |
| | Metformin | IP eq. to Sitagliptin 50mg | | Eris Lifesciences | |
| | Hydrochloride and | Metformin Hydrochloride IP | | Limited | |
| | Glimepiride Tablets | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 33 | Dapagliflozin, | Each film coated tablet contains: | 1 Tablet | M/s Sun Pharma | 15.15 |
| | Metformin | Dapagliflozin Propanediol | | Laboratories Limited | |
| | Hydrochloride | Monohydrate eq. to Dapagliflozin | | | |
| | Extended | 10mg | | | |
| | Releaseand | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 500mg (As extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 34 | Dapagliflozin, | Each film coated tablet contains: | 1 Tablet | M/s Sun Pharma | 13.47 |
| | Metformin | Dapagliflozin Propanediol | | Laboratories Limited | |
| | Hydrochloride | Monohydrate eq. to Dapagliflozin | | | |
| | Extended | 10mg | | | |
| | Releaseand | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 500mg (As extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 35 | Dapagliflozin, | Each film coated tablet contains: | 1 Tablet | M/s Sun Pharma | 16.00 |
| | Metformin | Dapagliflozin Propanediol | | Laboratories Limited | |
| | Hydrochloride | Monohydrate eq. to Dapagliflozin | | | |
| | Extended | 10mg | | | |
| | Releaseand | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg (As extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 36 | Dapagliflozin, | Each film coated tablet contains: | 1 Tablet | M/s Sun Pharma | 14.50 |
| | Metformin | Dapagliflozin Propanediol | | Laboratories Limited | |
| | Hydrochloride | Monohydrate eq. to Dapagliflozin | | | |
| | Extended | 10mg | | | |
| | Releaseand | Metformin Hydrochloride IP | | | |
| | Glimepiride Tablets | 1000mg (As extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 37 | Linagliptin + | Each film coated bilayered tablet | 1 Tablet | M/s Exemed | 14.37 |
| | Metformin | contains: | | Pharmaceuticals Ltd. / | |
| | Hydrochloride (ER) | Linagliptin 5mg | | M/s USV Private | |
| | Tablet | Metformin Hydrochloride IP | | Limited | |
| | | 1000mg (as Extended release) | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 38 | Linagliptin + | Each film coated bilayered | 1 Tablet | M/s Synokem | 14.72 |
| | Metformin | bilayered tablet contains: | | Pharmaceuticals Ltd. / | |
| | Hydrochloride (ER) | Linagliptin 5mg | | M/s Emcure | |
| | Tablet | Metformin Hydrochloride (as | | Pharmaceuticals | |
| | | Extended release) IP 1000mg | | Limited | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
| 39 | Linagliptin + | Each film coated bilayered tablet | 1 Tablet | M/s Exemed | 11.61 |
| | Metformin | contains: | | Pharmaceuticals Ltd. / | |
| | Hydrochloride (ER) | Linagliptin 5mg | | M/s Abbott Healthcare | |
| | Tablet | Metformin Hydrochloride (as | | Pvt. Ltd. | |
| | | Extended release) IP 1000mg | | | |
+-----+----------------------------------+-------------------------------------------------------------+-----------+----------------------------------------------+--------------+
Note:
(a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/252/120/2024/F/F. No. 8(120)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director (Pricing)
ADDENDUM
New Delhi, the 2nd February, 2024
S.O. 424(E).—The National Pharmaceutical Pricing Authority's Order No. 1571(E) dated 31st March 2023
and addendum issued vide S.O. 4887(E) dated 10th November, 2023, published in the Gazette of India, Extraordinary,
related to ceiling price fixation of scheduled formulation packs of I.V. fluids (non-Glass with special features) is
henceforth to be read with the following additions:
(1) Sl. No. 26 shall be added in Table 'B' as below:
+--------+---------------------------------+-----------------------------------------------------------+
| Sl. No. | Name of Manufacturer | Product/Brand Name |
+========+=================================+===========================================================+
| (1) | (2) | (3) |
+--------+---------------------------------+-----------------------------------------------------------+
| 26. | M/s Promea Therapeutics Pvt. Ltd | LDPE Bottle/ Non-Glass container with |
| | | special features- Eurohead Cap |
+--------+---------------------------------+-----------------------------------------------------------+
(2) Clause (e2) is added after clause (e1) & shall be read as follows:
"(e2) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 26 of Table B, only the prices of the
formulations specified in Sl. No. 2, 4, 5 & 7 of Table A are applicable."
[PN/252/120/2024/F/F. No. 8(120)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director (Pricing)
ADDENDUM
New Delhi, the 2nd February, 2024
S.O. 425(E).- The National Pharmaceutical Pricing Authority's Order No. 1570(E) dated 31st March 2023
and addendum issued vide S.O. 4888(E) dated 10th November, 2023, published in the Gazette of India, Extraordinary,
related to ceiling price fixation of Ringer lactate injection in pack having special features is henceforth to be read with
the following additions:
(1) Sl. No. 19 shall be added in Table 'B' as below:
+--------+---------------------------------+
| Sl. No. | Name of Manufacturer |
+========+=================================+
| (1) | (2) |
+--------+---------------------------------+
| 19. | M/s Promea Therapeutics Pvt. Ltd. |
+--------+---------------------------------+
(2) Clause (d2) is added after clause (d1) & shall be read as follows:
"(d2) In case of M/s Promea Therapeutics Pvt. Ltd. mentioned in Sl. No. 19 of Table B, only the prices of the
formulations specified in Sl. No. 3 of Table A are applicable.”
[PN/252/120/2024/F/F. No. 8(120)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director (Pricing)
ADDENDUM
New Delhi, the 2nd February, 2024
S.O. 426(E).- The National Pharmaceutical Pricing Authority's Order No. 1576(E) dated 31st March 2023
and addendum issued vide S.O. 4889(E) dated 10th November, 2023, published in the Gazette of India, Extraordinary,
related to ceiling price fixation of the scheduled formulation as specified therein is henceforth to be read with the
following additions:
(1) Sl. No. 6 shall be added in Table 'B' as below:
+--------+---------------------------------+
| Sl. No. | Name of Manufacturer |
+========+=================================+
| (1) | (2) |
+--------+---------------------------------+
| 6. | M/s Promea Therapeutics Pvt. Ltd. |
+--------+---------------------------------+
[PN/252/120/2024/F/F. No. 8(120)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director (Pricing)
ADDENDUM
New Delhi, the 2nd February, 2024
S.O. 427(E).- The National Pharmaceutical Pricing Authority's Order No. 1569(E) dated 31st March 2023
and addendum issued vide S.O. 4891(E) dated 10th November, 2023, published in the Gazette of India, Extraordinary,
related to ceiling price fixation of the scheduled formulation as specified therein is henceforth to be read with the
following additions:
(1) Sl. No. 6 shall be added in Table 'B' as below:
+--------+---------------------------------+
| Sl. No. | Name of Manufacturer |
+========+=================================+
| (1) | (2) |
+--------+---------------------------------+
| 6. | M/s Promea Therapeutics Pvt. Ltd. |
+--------+---------------------------------+
[PN/252/120/2024/F/F. No. 8(120)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director (Pricing)
Login to read full text